Sedana Medical applies for market approval in Italy
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an application for market approval for Sedaconda (isoflurane) for inhaled sedation in intensive care in Italy.“With the application in Italy, we are hoping to bring our Sedaconda products to yet another important European market. Having received market approval in 14 European countries to date, we are aiming to receive further approvals in Poland, Italy, Switzerland, and the UK during 2022. This would allow us to offer the first and only on-label therapy for inhaled sedation of mechanically